The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores.
Macrophage inhibitory cytokine-1/growth differentiation factor 15 (MIC-1/GDF15), a divergent member of the TGF-beta superfamily is induced by a range of proinflammatory cytokines and oxidized low-density lipoprotein (oxLDL) and is highly expressed in macrophages in atherosclerotic and tumor lesions. MIC-1/GDF15, a major p53 target gene, is largely described to have anti-tumorigenic activity and more recently high MIC-1/GDF15 serum levels in late stage cancer were shown to be the major cause of cancer-associated weight loss. MIC-1/GDF15 serum levels independently predict both atherosclerotic events and severity of rheumatoid arthritis (RA), suggesting serum levels are important in modifying disease expression. Controlling serum levels is the ratio of latent unprocessed MIC-1/GDF15 stromal stores to soluble mature MIC-1/GDF15 generated by the cell. Here, we investigate MIC-1/GDF15 secretion from U937 monocytoid cells and identify novel mechanisms designed to ensure secretion of unprocessed cytokine and creation of latent stromal stores. We find that endogenous MIC-1/GDF15 is secreted as both processed and unprocessed forms. Pulse chase analysis of MIC-1/GDF15 secretion reveals that unprocessed MIC-1/GDF15 precursor is rapidly secreted, while mature MIC-1/GDF15 generated within the cell by intracellular processing is secreted much slower, possibly via an alternate secretory route. The COOH-T 47 amino acids of the propeptide are responsible for rapid secretion of MIC-1/GDF15 precursor and this effect occurs in the trans-Golgi network (TGN)/post TGN compartment. Thus, variations in MIC-1/GDF15 intracellular processing, regulating the presence or absence of propeptide, are a powerful mechanism modulating rate of MIC-1/GDF15 secretion and proMIC-1/GDF15 stromal storage, with major impact on circulating levels of mature MIC-1/GDF15.
Bauskin
Asne R
AR
St. Vincent's Centre for Applied Medical Research, St. Vincent's Hospital and University of New South Wales, Sydney, Australia. a.bauskin@cfi.unsw.edu.au
Jiang
Lele
L
Luo
X Wei
XW
Wu
Liyun
L
Brown
David A
DA
Breit
Samuel N
SN
D001172:Arthritis, Rheumatoid / Q000276:immunology; D050197:Atherosclerosis / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D015687:Cell Hypoxia / Q000187:drug effects / Q000276:immunology; D003001:Cloning, Molecular; D003035:Cobalt / Q000494:pharmacology; D055436:Growth Differentiation Factor 15 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007114:Immunization; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D009369:Neoplasms / Q000276:immunology; D011499:Protein Processing, Post-Translational / Q000187:drug effects / Q000276:immunology; D055571:Secretory Pathway / Q000187:drug effects / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000276:immunology; D019076:Transgenes / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology; D020298:U937 Cells
C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15; D008070:Lipopolysaccharides; D016212:Transforming Growth Factor beta; D003035:Cobalt; D014212:Tretinoin; C018021:cobaltous chloride